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Abstract
Aim
Knowledge of the quality of antimicrobial therapy (AMT) used for invasive healthcare-asso-
ciated infections (HAIs) in paediatrics is scarce. Influence of the final information about the
isolated pathogen on the subsequent targeted AMT was investigated in our study.
Methods
Data on 149 children (0–17 years) with blood culture positive HAIs were collected. The
causative microbes under investigation were Staphylococcus aureus, Staphylococcus epi-
dermidis, streptococci, Gram negative rods, and mixed infections were likewise included.
For adjusting the antimicrobial regimen, an expert panel evaluated the quality of the tar-
geted AMT and the delay of 72 hours after final microbiology results. AMT was regarded as
inappropriate if the pathogen was totally resistant to the used antimicrobials (i) or if the cho-
sen therapy was of not optimal efficacy against the pathogen (ii).
Results
17% of the patients received inappropriate AMT. Half of these infections 13/26 (50%) were
treated with an antimicrobial to which the isolate was resistant. Three (3/13, 23%) of these
patients received antimicrobials which were totally ineffective according to in vitro data.
Suboptimal or too broad spectrum AMT was administered to 13/26 (50%) patients. The
most common causes of inappropriate use were the use of beta-lactams in oxacillin-resis-
tant Staphylococcus epidermidis infections and vancomycin given in oxacillin-sensitive
Staphylococcus aureus infections.
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Conclusion
Approximately 17% of the selected cohort received inappropriate AMT. More attention
should be paid to the appropriate use of antimicrobials, and training of prescribers should
be urgently provided.
Introduction
Bloodstream infections (BSIs) are among the most common healthcare-associated infections
(HAIs) in pediatrics [1,2,3]. They cause substantial morbidity and mortality, increase health
care costs and often result in a prolonged hospital stay [4]. They are caused by a vast variety of
pathogens [5,6,7] and when a BSI is suspected, rapid initiation of empirical antimicrobial ther-
apy (AMT) is of high importance. The selection of appropriate therapy is, however, challenging
since it should cover the most likely causative pathogens. It has been shown by Welsh et al. [7]
that selection of suboptimal therapy affects the prognosis of the children.
On the other hand, the use of an excessively broad spectrum antimicrobial therapy can
expose the patient to opportunistic infections caused by multiresistant organisms, fungi or
Clostridium difficile. In addition, multiple co-morbidities of the patients and several side effects
of the antibiotics further complicate the choice of appropriate therapies.
Both HAIs and resistant bacteria are becoming more common, and development of new
antimicrobials is scarce. Inappropriate use of AMT occurs in different ways such as the pre-
scribing antibiotics with no or suboptimal efficacy against the pathogens. On the other hand, if
the blood culture is positive, targeting the AMT should be executed promptly in order to opti-
mize the therapy. In addition, failure of de-escalation of the therapy should be considered inap-
propriate as well.
The aim of our study was to investigate retrospectively the appropriateness of the prescribed
targeted AMT in pediatric patients with healthcare-associated BSIs caused by different patho-
gens. For that purpose we created five different groups of infections based on different pathogens.
The causative microbes were the following: Staphylococcus aureus, Staphylococcus epidermidis,
streptococci, Gram negative rods, and mixed infections. In particular, the study focused on how
the blood culture results were taken into account after the microbiological information was
obtained, i.e. whether the data influenced the subsequent choice of antimicrobials or not. We
allowed the colleagues 72 hours (study period) to respond to the final blood culture results.
Methods
Study design and participants
The Hospital for Children and Adolescents, Helsinki University Central Hospital, Finland, is a
tertiary-care paediatric centre with 130 beds and approximately 100 annual blood culture posi-
tive BSIs. The most common blood isolates have been coagulase negative staphylococci (CONS)
covering approx. 50% of all isolates. In order to obtain a more heterologous material for our
analysis we decided to create five different groups of blood culture positive infections caused by
different pathogens (Staphylococcus aureus, Staphylococcus epidermidis, streptococci, Gram neg-
ative rods, and polymicrobial infections). This was done due to the natural occurrence of the
causative bacteria in BSIs. Since Gram positive bacteria are the causative agents in most cases.
We likewise aimed at collecting Gram negative bacteria since they are generally more virulent
and more complex to treat. The aim was to gather approximately 30 patients/group.
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Data from patients who suffered from infections caused by S. aureus, S. epidermidis, strepto-
cocci, Gram negative rods and polymicrobial infections were collected retrospectively in the
order of appearance from June 2012 backwards (Fig 1). Due to the fact that S. epidermidis
infections may often be caused by contaminants from the skin, patients with this bacterium
were screened carefully into this study in order to include only those patients who had a blood
culture positive infection (in most cases: fever and elevated leukocytes were present). Infections
caused by fungi and anaerobes were uncommon, and were therefore not analyzed.
The following characteristics were recorded for each patient (if available): age, gender, dura-
tion of hospitalization, diagnosis and co-morbidities, weight, height, drug allergies, the use of
antimicrobials 7 days prior to the diagnosis, the date of blood sample taken, the date of final
blood culture results (i.e. when pathogen was identified and the antibiogramme was given), leu-
kocytes (neutrophils), empirically used antimicrobials, duration of empirical AMT days prior
to receiving blood culture results, the antimicrobials selected after the blood culture result. For
all antimicrobials used, we recorded: the duration of AMT in days in total, antimicrobial used,
dosing, formulation and duration of therapy individual antimicrobial. Our surveillance period
was from seven days prior to receiving the positive blood culture to 30 days after the AMT for
a healthcare-associated BSI was stopped or to the death of a patient.
Evaluation of the appropriateness of the targeted antimicrobial therapy
The main focus of the study was the use of antimicrobials during the 72-hour time window
immediately after the final data of a positive blood culture was provided by the microbiology
laboratory. Thus, the physician(s) in charge were allowed 72 hours to respond to the microbio-
logical data. If necessary changes in AMT were not made during this given time period (of 72
hours), the targeted AMT was considered inappropriate. The 72-hour time window is com-
monly used when assessing the appropriateness of AMT. The quality of the given targeted
AMT for each patient was evaluated retrospectively by an expert panel of three physicians:
microbiologist (MV) and two infectious diseases consultants (V-JA and HS). Decision over
whether the AMT of a particular patient was inappropriate or not, was a consensus. This study
did not evaluate the initial empiric therapy.
When evaluating the quality of therapy for healthcare-associated BSI, the following demo-
graphic characteristics were taken into account by the panel: age, co-morbidities, causative
pathogen/pathogens, temperature (if the patient had fever) and the level of granulocytes. A leu-
kocyte count of< 1,0 x 109/L was considered as neutropenia.
Inappropriate targeted AMT was divided into two categories: 1) the isolated pathogen was
resistant to the selected antimicrobial(s), 2) the isolated pathogen was either treated with an
antimicrobial with suboptimal efficacy or the pathogen was treated with too broad spectrum
agents, the therapy thus not being optimal. Each patient was categorized into one category
solely according to the clinical significance of the inappropriateness of AMT. The analysis used
in the study was both quantitative and qualitative.
Methods and definitions
Hospital-acquired bacteremia was determined according to the classic CDC criteria, where lab-
oratory-confirmed bloodstream infection is LCBI [8]. LCBI is equivalent to the determination
of healthcare-associated BSI in our study.
Flow chart of the selected patients is shown in Fig 1.
The study was reviewed and approved by the local Ethical Committee forWomen and Children
(HUCH, Helsinki University Central Hospital, Finland). Due to the nature of this study (retrospec-
tive registry study), no written or verbal consent from the guardians of the children were needed.
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This study was a retrospective analysis regarding information found from patient records
(paper and electronic). Patient records/information was anonymized and de-identified prior to
analysis.
Results
Patient profiles and epidemiology
Demographic data of the cohort of 149 patients with different causative bacteria are given in
Table 1. 72/149 (48%) patients were both term and preterm neonates ( 28 days of age), the
age of 24/149 (16%) was between 29 days and 1 year, 39/149 (26%) were between the age of 1
and 12 years and 14/149 (9%) were between the age of 12 and 17 years. The most common
malignancy was acute lymphoblastic leukemia and the most common cause of surgery was
congenital heart malformation.
Organisms of the streptococcal cohort were the following: Streptococcus agalactiae (Group
B streptococci, GBS), (18/30, 60%), Streptococcus viridans (7/30, 23%), Streptococcus pyogenes
(3/30, 10%), Streptococcus pneumoniae (1/30, 3%) and Streptococcus salivarus (1/30, 3%)
(Table 1). All of the children infected by GBS were neonates.
The staphylococcal cohorts consisted of patients infected with Staphylococcus aureus
(n = 25) or Staphylococcus epidermidis (n = 33). S.aureus was most common on surgical
patients (8/25, 32%), S.epidermidis in patients with malignancies (12/33, 36%) (Table 1). No
MRSA infections were recorded.
The Gram negative cohort consisted of the following: Escherichia coli (19/38, 50%) followed
by Klebsiella pneumoniae and oxytoca (6/38, 16%), Pseudomonas aeruginosa (4/38, 11%),
Enterobacter cloacae (3/38, 8%), Serratia marcescens (2/38, 5%), Citrobacter (n = 1),
Fig 1. Flow chart of patients selected for the study. The five pathogen groups chosen for the study were: Gram negative bacteria, Polymicrobial
infections, Staphylococcus aureus, Staphylococcus epidermidis and streptococcal species.
doi:10.1371/journal.pone.0141555.g001
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Stenotrophomonas maltophilia (n = 1), Sphingomonas paucimobilis (n = 1), and an unidentified
Enterobacteriaceae strain (n = 1). Two patients suffered from bacteremia caused by an ESBL
strain of E.coli.
Causative microbes of the polymicrobial group were the following: Gram+ Gram+ (9/23,
39%), Gram+ Gram- (9/23, 39%) and Gram- Gram- (5/23, 22%). In the case of two polymicro-
bial infections, three different pathogens were isolated form the blood culture.
Adjusting the empirical use of antimicrobials
The initial empirical antimicrobial therapy of 114 patients (77%) was changed during the study
period within three days (72 hours) after receiving the final blood culture results. Empirical
AMT was changed in 87% of cases in the polymicrobial infection group (20/23). In the other
groups the treatments were changed as follows: Staphylococcus aureus 20/25 (80%), Staphylo-
coccus epidermidis 26/33 (79%), Gram negative bacteria 27/38 (71%) and streptoccocci 21/30
(70%).
Inappropriate use of targeted antimicrobials
AMT was considered totally inappropriate in three cases because the pathogen was resistant to
all prescribed antimicrobials (Table 2) In one case oxacillin resistant S. epidermidis (MRSE)
was treated with cloxacillin, in another case MRSE was treated with cefuroxime and fluoro-
quinolone to which the strain was also resistant. One child received cefuroxime monotherapy
for Pseudomonas sp.
Ten patients received at least one antimicrobial agent to which the pathogen was resistant
(Table 3). Five children with MRSE infections were treated with beta-lactams. Two patients
with infections caused by Klebsiella received vancomycin. One child with an ampicillin-resis-
tant Citrobacter freundii infection was treated with ampicillin. One child with a cefuroxime-
resistant Stenotrophomonas infection was treated with cefuroxime and one child with E. coli
resistant to ciprofloxacin and penicillin was treated with ciprofloxacin and penicillin G.
Out of all 149 cohort patients, 13 (9%) received inappropriate AMT due to suboptimal or
too broad spectrum efficacy of the agent (Table 4). The most common cause for not optimal
Table 1. Demographic data of the selected patients with healthcare-associated bloodstream infections (n = 149).
Pathogen group/co-
morbidities
Patients/
pathogen group
Full term
neonates(<28
days)
Premature neonates
(born < 37 weeks old)
Patients with
malignancies
*Surgical
patients
^Other co-
morbidities
no of patients,
(%)
no of patients,
(%)
no of patients, (%) no of patients, (%) no of
patients, (%)
no of patients,
(%)
Staphylococcus
aureus
25 (17) 3 (12) 6 (24) 5 (20) 8 (32) 3 (12)
Staphylococcus
epidermidis
33 (22) 1 (3) 8 (24) 12 (36) 10 (30) 2 (6)
Streptococcal species 30 (20) 18 (60) 4 (13) 5 (17) - 3 (10)
Gram negative
bacteria
38 (26) 8 (21) 14 (37) 3 (8) 9 (24) 4 (11)
Polymicrobial
infections
23 (15) 1 (4) 9 (40) 12 (52) 1 (4) -
Total 149 (100) 31 (21) 41 (28) 37 (25) 28 (19) 12 (8)
*Surgical patients were patients who had undergone surgery during the same hospital admission as they had BSI.
^Other co-morbidities were deﬁned as patients with co-morbidities that could not be classiﬁed to any of the given categories.
doi:10.1371/journal.pone.0141555.t001
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use of AMT was the use of vancomycin in methicillin-sensitive S.aureus (MSSA) (n = 6) infec-
tions and in one methicillin-sensitive S. epidermidis (MSSE) infection. One MSSA infection
was treated with penicillin G (and ceftriaxone) and one MSSA with both intravenous cefurox-
ime and oral cephalexin. One child with a penicillin-sensitive Streptococcus viridans was treated
with meropenem, and one child with an Enterobacter cloacae infection received cefuroxime
monotherapy. Finally, one patient with a mixed infection caused by E. cloacae and Enterococcus
faecalis received meropenem–an agent with suboptimal activity against the enterococcus.
Another mixed infection caused by Enterococcus faecalis and an oxacillin-resistant Staphylococ-
cus sp was treated with vancomycin, ampicillin and meropenem. Meropenem use was consid-
ered unnecessary.
Inappropriate AMT was found to be most common in the treatment of BSIs caused by
Staphylococcus aureus (8/25, 32%) (Fig 2). On the contrary, inappropriate AMT was uncom-
mon in infections caused by streptococcal species: only one patient, with ampicillin sensitive
Streptococcus viridans, received inappropriately meropenem (1/30, 3%).
Lack of de-escalation, too broad spectrum AMT, was a concern in the case of two patients:
S.viridans infection treated with meropenem, and a polymicrobial infection (caused by Entero-
coccus faecalis and staphylococcal species) treated with meropenem (Table 4).
Outcome of antimicrobial therapy
Mortality rate was low. From the cohort (N = 149 patients), seven patients died (5%). Out of
these seven patients, infection was the main cause of death in two cases. Three of the fatal
deceased premature neonates (< 1 kg) with BSIs caused by E. coli, one premature neonate (< 2
kg) with a malignancy had S. epidermidis BSI, one premature neonate (< 2,5 kg) had a BSI
caused by E. cloacae, one infant 6 months of age with a malignancy had a S. aureus BSI, one
infant 9 months of age with a malignancy had a BSI caused by S. epidermidis + S. viridans.
Table 2. Patients (n = 3) who were prescribed an entirely inappropriate therapy* due to resistance of the pathogen. Antimicrobial therapy (AMT)
given 0 to 72 hours after identification of the pathogen and testing its antimicrobial sensitivity. AMT was given parenterally (IV).
Age Co-morbidities Isolate Resistant to AMT given
< 12months left ventricular hypoplasia S. epidermidis oxacillin cloxacillin*
< 12months biliary atresia S. epidermidis clindamycin oxacillin levoﬂoxacin ceftriaxone* ciproﬂoxacin
< 5 years transposition of great arteries Pseudomonas sp. cefuroxime cefuroxime*
doi:10.1371/journal.pone.0141555.t002
Table 3. Patients (n = 10) who were prescribed an inappropriate therapy* due to resistance of the pathogen to one of the chosen antimicrobials.
Antimicrobial therapy (AMT) given 0 to 72 hours after identification of the pathogen and testing its antimicrobial sensitivity. AMT is given parenter-
ally (IV) if not mentioned otherwise.
Isolate N Pathogen resistant to AMT given
S. epidermidis 1 oxacillin cefuroxime* netilmycin
S. epidermidis 1 oxacillin cefuroxime* clindamycin
S. epidermidis 1 oxacillin cefuroxime* metronidazole
S. epidermidis 1 oxacillin vancomycin meropenem*
S. epidermidis 1 oxacillin teicoplanin meropenem*
Citrobacter sp. 1 ampicillin penicillin G* netilmycin
Stenotrophomonas maltophilia 1 cefuroxime cefuroxime* trimethoprim-sulfamethoxazole (PO)
E. coli 1 cefuroxime (ESBL) ciproﬂoxacin penicillin G* meropemen ciproﬂoxacin*
Klebsiella pneumoniae 1 vancomycin vancomycin* cefuroxime
Klebsiella pneumoniae 1 vancomycin vancomycin* metronidazole cefuroxime
doi:10.1371/journal.pone.0141555.t003
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Table 4. Patients (n = 13) who were prescribed a suboptimal or too broad spectrum AMT. The chosen therapy was too broad-spectrum^ or of sub-
optimal efficacy* or involved concomitant use of antimicrobials of the same class • (eg. cephalosporins) against the pathogen. Antimicrobial ther-
apy (AMT) given 0 to 72 hours after identification of the pathogen and testing its antimicrobial sensitivity. AMT is given parenterally (IV) if not
mentioned otherwise.
Isolate N Reported as AMT given
S. aureus 2 oxacillin S vancomycin*ceftazidime
S. aureus 1 oxacillin S vancomycin* ceftriaxone
S. aureus 1 oxacillin S vancomycin* meropenem
S. aureus 1 oxacillin S vancomycin* cefuroxime
S. aureus 1 oxacillin S vancomycin* netilmycin
S. aureus 1 oxacillin S penicillin G* ceftriaxone
S. aureus 1 oxacillin S cefuroxime • cefalexine • (PO)
S. epidermidis 1 oxacillin S vancomycin* netilmycin
S. viridans 1 ampicillin S meropenem^
Enterobacter cloacae coliform rod 1 ampicillin R cefuroxime*§ (monotherapy)
E. cloacae, Enterococcus faecalis Streptococcal species 1 ampicillin R ampicillin S meropenem*§§ (suboptimal enterococcal Rx)
Enterococcus faecalis Staphylococcal species 1 ampicillin S oxacillin R vancomycin meropenem^ ampicillin
§ therapy of E. cloacae with cefuroxime monotherapy not optimal
§§ therapy of E. faecalis with meropenem not optimal
doi:10.1371/journal.pone.0141555.t004
Fig 2. 26 patients (26/149, 17%) received inappropriate AMT in 0 to 72 hours after receiving blood culture results.
doi:10.1371/journal.pone.0141555.g002
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Neither of these patients died due to inappropriate AMT. However, the study design did not
allow us to demonstrate a causal relationship between the patients that died and inappropriate
AMT.
Discussion
Summary of key findings
To our knowledge, this is the first study investigating the quality of AMT in children with
healthcare-associated BSIs. We focused on one hand on the vigilance of physicians in respond-
ing to microbiological results and on the other hand on the appropriateness of the targeted
antimicrobial therapy. Our approach of using a selected cohort consisting of different causative
pathogens did not allow us to calculate the total magnitude of inappropriate use of antimicrobi-
als of all blood culture positive infections at our hospital. It did, however, give us a general pic-
ture of what pathogens were most often targeted with inappropriate AMT.
In all, we discovered that 77% of the patients in the cohort had their empirical AMT
changed after receiving the final blood culture results, and 17% of these patients with health-
care-associated BSIs received inappropriate targeted AMT. The microbiological results were
frequently either totally (2%) or partly ignored (17%) in the design of the subsequent treat-
ment. Similarly, the choice of antimicrobial agents with suboptimal or too broad spectrum effi-
cacy was not uncommon (9%). To our surprise, inappropriate use of vancomycin in treating
MSSA was the most frequent cause of inappropriate use. The second most common misuse
was treatment of MRSE infections with beta-lactams. In all, beta-lactams were the most often
misused group of antimicrobials.
Inappropriate AMT was not associated to mortality. In general, AMT should have been
given to the patients included in this study. All of the patients included had blood culture posi-
tive infections with pathogens identified from the blood. In some cases pathogens might have
been contaminants with relatively minor virulence, hence it might suggest that AMT was not
necessary in all cases.
Literature and inappropriateness of antimicrobial therapy
Investigating the quality of AMT is a complex topic entailing multiple factors to be considered.
The quality of AMT, i.e. appropriate vs. inappropriate therapy, has not been studied exten-
sively. Majority of the studies have focused on infections in adults. These studies have applied
different approaches and used a large variety of definitions of appropriate AMT. This diversity
makes it difficult to relate our results to those published earlier. The most often used approach
has been evaluation of empiric therapy of serious infections [9,10,11]. Some studies have, how-
ever, also looked at targeted therapy [12,13,14,15,16,17]. Part of the studies focused especially
on verified BSI [9,10,11,16] while others focused on the quality of the AMT in general
[12,13,15,17].
Six of the studies used relatively simple definitions of inappropriate AMT
[9,10,11,13,15,16]. One study Davey et al. [13], defined the AMT inappropriate if the pathogen
was resistant to the used antimicrobial agent or initiation of appropriate AMT was delayed.
This study concluded that if a patient received appropriate empirical AMT and the therapy
was thereafter promptly targeted, the outcome was better than if the empirical AMT had been
inappropriate, but had been switched to appropriate targeted therapy. Appropriate targeted
AMT is therefore of crucial importance especially if the empirical AMT has been inappropri-
ate. In our study the empirical AMT of 77% of patients was changed after receiving the final
blood culture results.
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Other studies had used more complex and detailed definitions on the appropriateness of
AMT [12,14,17]. Willemsen I. et al. used a score system in order to evaluate the appropriateness
of the AMT [17]. The score system divided their therapies into five different categories: correct
decision, incorrect decision, incorrect choice, incorrect use and data missing. They further spec-
ulated that upon evaluating incorrect use, also the following parameters should be taken into
account: dosage, timing, administration and duration of therapy. Due to the retrospective nature
of our study and the fact that we evaluated solely the choice of antibiotics, we may assume that
the frequency of inappropriate use of AMT was even higher than that reported.
Regarding the choice of antimicrobial, excessive use of vancomycin is reported by several
studies. The study of Cosgrove SE. et al. investigated prospectively clinicians´ antimicrobial
prescriptions for different empirical healthcare infections [12]. AMT was criticized in 30%
(334/1104) of the cases. In 60/334 (18%) cases unnecessary use of vancomycin was recorded
[12]. Patel SJ. et al. investigated the use of AMT in neonatal infections [18]. Their main find-
ings were similar to those of ours: the most often misused antimicrobials were vancomycin and
carbapenems. The reason for excessive use of vancomycin is not clear. One reason may be that
many guidelines of empiric therapy include vancomycin but once the data on the pathogen is
exposed, de-escalation is not executed. Increased provider awareness of drug-resistant CONS
probably also increases the overall use of vancomycin. Similar findings have been published by
Levy ER et al. [19].
Two studies investigated whether local or national guidelines or recommendations were fol-
lowed [15,17]. In the study of Raineri et al. a systematic infectious diseases specialist consulta-
tion program was implemented in ICU setting and after the implementation, adherence to
local guidelines regarding empirical AMT was increased by more than 20% (63% vs. 84%) [15].
Willemsen I. et al. also investigated the appropriateness of AMT and found out that during six
prevalence studies conducted in 2001 to 2004, the appropriateness of AMT did not vary appre-
ciably. The appropriateness of AMT was evaluated against the local AMT prescription guide-
lines. Out of 938 patients with AMT, 351 (37%) received inappropriate AMT. Compared with
our results, this indicates more inappropriate use of AMT when compared to our results, but it
must be taken into account that our study evaluated only the choice of the antimicrobial and
targeted AMT instead of empirical AMT.
The proportion of patients receiving inappropriate AMT has varied between studies. The
percentage of patients receiving inappropriate AMT varied (20–24%) in empirical AMT
[10,11,14] and in targeted AMT (16–37%) [14,15,16]. Due to the small number of studies
investigating the appropriateness of AMT, it is unclear how often inappropriate AMT has been
used in the treatment of patients with HCA BSIs. The results of our study (17% of inappropri-
ate use of AMT) are, however, in line with the above-mentioned studies.
Appropriate empirical AMT for BSI is known to reduce mortality in empirical sepsis [10]
and in enterococcal infections [16]. In addition, Erbay A. et al. showed that in bacteremias
caused by Acinetobacter baumanii infections a 26% reduction in the overall crude mortality
rate was achieved with adequate early empirical antimicrobial therapy compared with inade-
quate therapy [9]. Similarly, Kumar A. et al. showed that inappropriate empirical AMT in sep-
tic shock was associated with a five-fold increase in mortality [14]. In addition, Raineri E. et al.
demonstrated in patients with different types of serious infections that appropriate AMT was
associated with decreased mortality [15]. In contrast to these studies, Zaragoza R. et al. showed
that inappropriate AMT was not associated with increased mortality [11]. This finding is in
accord with our study where the inappropriate AMT was not associated with increased mortal-
ity. A plausible reason for this is that the infections in our hospital were rarely fatal due to the
low virulence of the causative pathogens. Hence, most of the patients receiving inappropriate
AMT suffered from infections caused by CONS.
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Limitations
Our study involved several limitations. Firstly, our study was retrospective and we were able to
collect only data that was recorded. Secondly, the number of patients in our study was relatively
small and therefore general assumptions regarding the overall occurrence of true faults are dif-
ficult to calculate. Thirdly, the antimicrobials used were evaluated by an expert panel. The clas-
sification (appropriate vs. inappropriate) was of course a subjective opinion of the panel. The
evaluation was, however, based on microbiological in vitro data. Fourthly, the pathogens iso-
lated from the blood cultures may not always represent the sole pathogens causing the infec-
tion. This may result in treating children with severe underlying conditions with broad-
spectrum drugs (‘just in case’).
Concluding remarks
Inappropriate therapy of blood-culture positive HAIs was not uncommon. In our cohort
unnecessary use of vancomycin in oxacillin-sensitive Staphylococcus aureus infections and
inadequate use of beta-lactams in oxacillin-resistant Staphylococcus epidermidis infections were
the most common causes of inappropriate use of antimicrobials.
The co-operation between clinicians, nurses and microbiology laboratory is of vital impor-
tance. At present the microbiologist informs the clinician about the blood culture findings.
Unfortunately, such service is provided only during office hours. In the future this communica-
tion must be improved. Multidisciplinary actions should be enhanced and new forms of multi-
disciplinary working taken into consideration. Example of a new approach could be the hiring
of an infectious diseases pharmacist. This approach has been used in many countries in differ-
ent settings relating to the rational use of antimicrobials and the impact has been good
[20,21,22,23].
The spectrum of pathogens isolated from invasive infections in our hospital was similar to
that reported from many other hospitals i.e. staphylococci are the most common causes of
infections. During the years 2005–2013, the most frequent isolate was S. epidermidis (46% of
isolates). S. aureus was isolated from 8% of HAIs. If these infections are in general treated with
antibiotics similar to those in our cohort, the absolute number of patients receiving inappropri-
ate antimicrobial agents is much higher than the numbers we have presented here.
Inappropriate use of AMT should not be overlooked. The results of our study were alarming
to us, and training of prescribers of antimicrobials by using the presented data has already been
initiated. The follow-up of consumption of antimicrobials in defined daily doses at different
locations of the Hospital has been initiated. Finally, launching an antimicrobial stewardship
program is in progress.
In the future, prospective studies should be carried out in order to further assess the appro-
priateness of AMT in children with severe HAIs. Regular audits regarding the appropriate use
of AMT could be conducted as point prevalence studies.
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